Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Neurocrine Is Seeing A Very Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin
12:36pm, Monday, 08'th Aug 2022
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Pha
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
08:30am, Friday, 05'th Aug 2022 The Motley Fool
NBIX earnings call for the period ending June 30, 2022.
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
09:15pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2022 Results - Earnings Call Transcript
08:24pm, Thursday, 04'th Aug 2022
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kevin Gorman - Chief Exec
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Thursday, 04'th Aug 2022
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
05:38pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
02:51pm, Friday, 29'th Jul 2022 Zacks Investment Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Biosciences
08:01am, Friday, 29'th Jul 2022
It's make-or-break time for Neurocrine Biosciences' essential tremors treatment, analysts say, as NBIX stock trends sideways. The post The Make-Or-Break Moment Is Here For Highly Rated Neurocrine Bios
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
04:20pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
02:02pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
01:40pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
02:13pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
03:35pm, Monday, 25'th Jul 2022 Zacks Investment Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
10 Best Low-Volatility Stocks to Buy Now
02:01pm, Monday, 25'th Jul 2022
The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just m
Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings
04:29pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.
